Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-25-011052
Filing Date
2025-03-20
Accepted
2025-03-20 17:18:43
Documents
107
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 1829594
2 ex4-1.htm EX-4.1 45758
3 ex19-1.htm EX-19.1 99562
4 ex21-1.htm EX-21.1 3022
5 ex23-1.htm EX-23.1 3809
6 ex31-1.htm EX-31.1 12167
7 ex31-2.htm EX-31.2 11970
8 ex32-1.htm EX-32.1 8389
9 ex32-2.htm EX-32.2 8272
10 ex19-1_001.jpg GRAPHIC 5243
  Complete submission text file 0001493152-25-011052.txt   8903338

Data Files

Seq Description Document Type Size
11 XBRL SCHEMA FILE bfri-20241231.xsd EX-101.SCH 66023
12 XBRL CALCULATION FILE bfri-20241231_cal.xml EX-101.CAL 104818
13 XBRL DEFINITION FILE bfri-20241231_def.xml EX-101.DEF 301367
14 XBRL LABEL FILE bfri-20241231_lab.xml EX-101.LAB 584567
15 XBRL PRESENTATION FILE bfri-20241231_pre.xml EX-101.PRE 473553
109 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 1066158
Mailing Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801
Business Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801 781-245-1325
Biofrontera Inc. (Filer) CIK: 0001858685 (see all company filings)

EIN.: 473765675 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-40943 | Film No.: 25757791
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)